ZA200609021B - Novel use of peptide compounds for treating essential tremor and other tremor syndromes - Google Patents

Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Info

Publication number
ZA200609021B
ZA200609021B ZA200609021A ZA200609021A ZA200609021B ZA 200609021 B ZA200609021 B ZA 200609021B ZA 200609021 A ZA200609021 A ZA 200609021A ZA 200609021 A ZA200609021 A ZA 200609021A ZA 200609021 B ZA200609021 B ZA 200609021B
Authority
ZA
South Africa
Prior art keywords
tremor
peptide compounds
novel use
syndromes
treating essential
Prior art date
Application number
ZA200609021A
Other languages
English (en)
Inventor
Stohr Thomas
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of ZA200609021B publication Critical patent/ZA200609021B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200609021A 2004-06-24 2006-10-30 Novel use of peptide compounds for treating essential tremor and other tremor syndromes ZA200609021B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58208404P 2004-06-24 2004-06-24

Publications (1)

Publication Number Publication Date
ZA200609021B true ZA200609021B (en) 2008-04-30

Family

ID=34970895

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200609021A ZA200609021B (en) 2004-06-24 2006-10-30 Novel use of peptide compounds for treating essential tremor and other tremor syndromes

Country Status (19)

Country Link
US (1) US7427601B2 (OSRAM)
EP (1) EP1758606A1 (OSRAM)
JP (1) JP5038892B2 (OSRAM)
KR (1) KR20070034477A (OSRAM)
CN (1) CN1964733B (OSRAM)
AR (1) AR049940A1 (OSRAM)
AU (1) AU2005256468B2 (OSRAM)
BR (1) BRPI0512622A (OSRAM)
CA (1) CA2566301C (OSRAM)
EA (1) EA013592B1 (OSRAM)
IL (1) IL179732A0 (OSRAM)
MX (1) MXPA06015010A (OSRAM)
MY (1) MY146509A (OSRAM)
NO (1) NO20070423L (OSRAM)
NZ (1) NZ551207A (OSRAM)
TW (1) TWI361693B (OSRAM)
UA (1) UA88166C2 (OSRAM)
WO (1) WO2006000397A1 (OSRAM)
ZA (1) ZA200609021B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
WO2007144195A2 (en) 2006-06-15 2007-12-21 Schwarz Pharma Ag Pharmaceutical composition with synergistic anticonvulsant effect
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2008070994A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US7747551B2 (en) * 2007-02-21 2010-06-29 Neurovista Corporation Reduction of classification error rates and monitoring system using an artificial class
US8829033B2 (en) 2009-09-23 2014-09-09 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20110281808A1 (en) * 2010-05-14 2011-11-17 Allmax Nutrition Inc. Composition and Method for Increasing Pre Workout Thermogenics
WO2012084126A2 (en) 2010-12-02 2012-06-28 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20180042903A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6197764B1 (en) * 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
NZ524687A (en) * 2000-08-17 2005-01-28 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2001286763C1 (en) 2000-08-25 2006-03-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants for treatment of pain
US7112612B2 (en) 2000-11-21 2006-09-26 Ucb S.A. N-alkylated GABA compounds, processes for their preparation and their use as medicaments
WO2002067931A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
EP1539145A2 (en) * 2002-09-13 2005-06-15 Eisai Co., Ltd. Method of treating tremors
DE60318749T2 (de) 2002-11-18 2009-01-22 Bioprospecting Nb Inc. Paralytisches peptid von der spitzmaus sowie dessen nutzung in der therapie von neuromuskulären krankheiten
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
TW200603823A (en) 2006-02-01
JP2008503533A (ja) 2008-02-07
AR049940A1 (es) 2006-09-13
AU2005256468A1 (en) 2006-01-05
MXPA06015010A (es) 2007-03-26
NO20070423L (no) 2007-03-22
WO2006000397A1 (en) 2006-01-05
NZ551207A (en) 2010-07-30
EP1758606A1 (en) 2007-03-07
CA2566301A1 (en) 2006-01-05
AU2005256468B2 (en) 2010-12-09
UA88166C2 (ru) 2009-09-25
CN1964733B (zh) 2012-05-23
KR20070034477A (ko) 2007-03-28
CA2566301C (en) 2011-06-14
IL179732A0 (en) 2007-05-15
CN1964733A (zh) 2007-05-16
EA200700108A1 (ru) 2007-06-29
EA013592B1 (ru) 2010-06-30
JP5038892B2 (ja) 2012-10-03
TWI361693B (en) 2012-04-11
MY146509A (en) 2012-08-15
BRPI0512622A (pt) 2008-03-25
US7427601B2 (en) 2008-09-23
US20050288234A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
ZA200609021B (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
EP1628530A4 (en) METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SEPSIA
IL174075A0 (en) 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
ZA200704677B (en) Compositions and methods for the treatment of autism
IL178860A (en) Certain chemical entities, preparations and processes
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
IL182643A0 (en) Novel composition and methods for the treatment of immune related diseases
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
EP1773369A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PEPTIDE TREATMENT
IL178591A0 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom
HK1099231A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
GB0408521D0 (en) Treatment of sepsis
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
EP1962882A4 (en) COMPOSITIONS AND METHOD FOR TREATING DIABETES
IL181762A0 (en) Methods of treating symptoms of multiple sclerosis using vitamin d and related compounds
ZA200710476B (en) Methods and compositions for the treatment of pain
HK1096613A (en) Novel use of peptide compounds for treating pain in trigeminal neuralgia